75996 Federal Register / Vol. 69, No. 243 / Monday, December 20, 2004 / Notices 

limitations imposed by the review and 

funding cycle.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel 

Neurogenesis/Neuronal Development. 

Date: December 21, 2004. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Carl D. Banner, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4138, 

MSC 7850, Bethesda, MD 20892, (301) 435–

1251, bannerc@csr.nih.gov.

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS)

Dated: December 10, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–27722 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review, Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4), and 552b(c)(6), Title 5 

U.S.C., as amended. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy.

Name of Committee: Center for Scientific 

Review Special Emphasis Panel CommunityBased Colorectal Cancer Screening. 

Date: December 20, 2004. 

Time: 11:15 a.m. to 12:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Michael Micklin, PhD, 

Chief, RPHB IRG, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 3136, MSC 7759, 

Bethesda, MD 20892, (301) 435–1258. 

micklinm@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel End of Life 

Transitions. 

Date: January 3, 2005. 

Time: 11 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge drive,Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Michael Micklin, PhD, 

Chief, RPHB IRG, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 3136, MSC 7759, 

Bethesda, MD 20892, (301) 435–1258. 

micklinm@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS.)

Dated: December 14, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–27778 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: 4′ and 4′,4′′-substituted-3-α-

(diphenylmethoxy) Tropane Analogs 

as Cocaine Therapeutics

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

license worldwide to practice the 

invention embodied in of U.S. Patent 

5,792,775, issued on August 11, 1998, 

entitled, ‘‘4′ and 4′,4′′-substituted-3-a-

(diphenylmethoxy) tropane analogs as 

cocaine therapeutics’ to Phase2 

Discovery, having a place of business in 

the state of Ohio. The field of use may 

be limited to the treatment of Attention 

Deficit Hyperactivity Disorder (ADHD). 

The United States of America is the 

assignee of the patent rights in this 

invention. This announcement is the 

first notice to grant an exclusive license 

to this technology.

DATES: Only written comments and/or 

application for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

February 18, 2005, will be considered.

ADDRESSES: Requests for a copy of the 

patent applications, inquiries, 

comments and other materials relating 

to the contemplated license should be 

directed to: Pradeep Ghosh, J.D., Ph.D., 

M.B.A., Technology Licensing 

Specialist, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–5282; Facsimile: (301) 402–

0220; e-mail: ghoshpr@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This 

technology relates to a family of tropane 

analogs that bind to dopamine 

transporters and can be used to image 

dopamine transporter binding sites, and 

to diagnose and/or monitor 

neurodegenerative disorders and 

developmental disabilities like ADHD. 

ADHD is a neurobiological-based 

developmental disability characterized 

by inattentiveness, impulsivity, and 

hyperactivity. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552.

Dated: December 13, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–27781 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–P